David J. Lloyd - Concepedia

Author

David J. Lloyd

Also Known As

D J Lloyd, D Lloyd, D. J Lloyd, D. J. LLOYD, D. J. Lloyd, D. Lloyd, D.J Lloyd, D.J. Lloyd, DAVID J. LLOYD, David J Lloyd

145

Publications

6.5K

Citations

H-Index

162

Concepts

All Affiliations

Amgen (United States)University of Aberdeen Aberdeen Maternity Hospital University of Leicester Genomics Institute of the Novartis Research Foundation

About

David J. Lloyd is an author at Amgen (United States) specializing in medicine, physiology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	31	2.4K
2	Engineering	9	9	335
3	Health Sciences	8	8	684
4	Natural Sciences	5	5	649
5	Business	1	1	42

David J. Lloyd

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice Jing Xu, David J. Lloyd, Clarence Hale, Diabetes	2008	1.1K
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy Sue Shackleton, David J. Lloyd, Stephen N.J. Jackson, Nature Genetics Cell BiologyLamin A/cMolecular BiologyLipid Synthesis	2000	695
SUN1 Interacts with Nuclear Lamin A and Cytoplasmic Nesprins To Provide a Physical Connection between the Nuclear Lamina and the Cytoskeleton Farhana Haque, David J. Lloyd, Dawn T. Smallwood, Molecular and Cellular Biology Nuclear StructureNuclear LaminaMolecular BiologyCytoskeletonNuclear Lamin A	2006	499
A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies David J. Lloyd Human Molecular Genetics	2002	317
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models Elizabeth A. Killion, Jinghong Wang, Junming Yie, Science Translational Medicine Glp-1r AgonistsAnti-obesity EffectsImmunologyAnti-gipr AntibodiesPharmacotherapy	2018	217
Pharmacologic Effects of FGF21 Are Independent of the “Browning” of White Adipose Tissue Murielle M. Véniant, Glenn Sivits, Joan Helmering, Cell Metabolism Metabolic SyndromeMetabolic DisorderMedicinePathologyFibroblast Growth Factor	2015	194
Expression of Endogenous Oncogenic<i>V600EB-raf</i>Induces Proliferation and Developmental Defects in Mice and Transformation of Primary Fibroblasts Kathryn Mercer, Susan Giblett, Stuart A. Green, Cancer Research	2005	177
Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Corinne Vigouroux, Jocelyne Magré, Marie‐Christine Vantyghem, Diabetes Metabolic SyndromeTypical FpldDevelopmental BiologyMendelian DisorderGenetic Disorder	2000	175
Classifying perinatal death: fetal and neonatal factors Edmund Hey, David J. Lloyd, J. S. Wigglesworth BJOG An International Journal of Obstetrics & Gynaecology	1986	171
Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Ten Centre Study Group. David J. Lloyd, P Duffty, G M Durbin, BMJ Artificial LungPremature BabiesNeonatologyPediatricsArtificial Surfactant	1987	155

Page 1